Ingen internetforbindelse — viser den gemte version af siden.

Grifols S.A

USUSD
← Til Screeneren

Grifols S.A (LSE:0RDU) — Drug Manufacturers - General. Antal børser, hvor selskabets aktier handles: 4. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

⚠ Forveksl dem ikke: der findes et andet firma med samme eller et meget lignende navn. Det er en separat registrering — tjek ticker, børs og registreringsnummer.
  • Grifols SA — GRF-P · MC ES Registreringsnummer ukendt

Om Virksomheden

Websted
grifols.com
Investorrelationer
grifols.com/en/investors
Sektor
Healthcare · Drug Manufacturers - General
Hovedkontor
NEW YORK, Spain
Administrerende Direktør
Jose Ignacio Abia Buenache
Ansatte
25 258
Grundlagt
1909
Børsnoteret Siden
23.11.2007 (LSE:0RDU)
Udestående Aktier
422.36 mio.
Free Float
418.2 mio.
Markedsværdi
7.57 mia. USD
Insidere
31.19%
Institutionelle Investorer
37.75%
Branche (SIC)
Pharmaceutical Preparations
Juridisk Form
5RDO
ISIN
ES0171996012
LEI
959800HSSNXWRKBK4N60
Udbetalingsgrad
≈7.7%
FCF
641 mio. EUR
Udbetaling / FCF
5%
Gæld
8.52 mia. EUR
11 år FCF
Udbyttestreak
1 år
Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 30.06.2026 (selskabets seneste rapport).
Beskrivelse

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

annonce

Børser og Tickere

BørsTickerValutaPrisType
US USA StocksGIFLF OTCUSD10.547 -5.24%almindelige aktier
LSE London Stock Exchange0RDU IOBEUR16.125 +0.00%almindelige aktier
MC Bolsa de MadridGRF primærEUR9.8 +1.43%almindelige aktier
VI Vienna Stock ExchangeGRF sekundærEUR9.962 +0.99%almindelige aktier

Kurs over 3 Måneder

stigningsdag faldsdag udbyttets ex-dato udbetalingsdatoHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Udbytte

Grifols S.A (GIFLF) udbetaler udbytte én gang om året.

Ex-DatoUdbetalingBeløb%TypeTicker
2026-07-012026-07-020.0824 EUR0.9 %ekstraordinærUS:GIFLF
2025-08-122025-08-130.1500 EUR1.2 %ekstraordinærUS:GIFLF

Største Ejere

EjerAndelAktierRapportdato
VANGUARD STAR FUNDS-Vang…1%4.28 mio.2026-04-30
VANGUARD TAX-MANAGED FUN…0.66%2.8 mio.2026-06-30
iShares Trust-iShares Co…0.49%2.08 mio.2026-07-31
DFA INVESTMENT DIMENSION…0.34%1.46 mio.2026-04-30
Dimensional ETF Trust-Di…0.25%1.07 mio.2026-04-30
iShares Trust-iShares MS…0.22%935 1282026-07-31
DFA INVESTMENT TRUST CO-…0.17%741 7722026-04-30
VANGUARD Intl Eqy. INDEX…0.16%696 5102026-04-30
SCHWAB STRATEGIC TRUST-S…0.16%676 4822026-05-31
VANGUARD Intl Eqy. INDEX…0.15%634 2982026-04-30
Pacer Advisors, Inc.0%1 3232026-06-30